“4/4 (100%) r/r AML patients with ASXL1 truncating mutations at the selected dose level achieved an overall response (CR/CRi/MLFS) and are alive,” $SLS ir.sellaslifesciences.com/news/News-Deta…

Meet our Board of Directors! Laura Badmaev founded the ARRE Foundation in 2018 and serves as the chair of the Board of Directors. Her son Alex has Bohring-Opitz Syndrome (ASXL1). Laura and her family live in Maine.

Meet our Board of Directors! Daniel Ordower joined the Board of Directors in 2021. His son Asher has Bohring-Opitz Syndrome (ASXL1). Daniel is the treasurer. He and his family live in New York City.

Meet our Board of Directors! Julie Lopez has served as a volunteer since 2018 and joined the board in 2021. She manages our research grant program and other research initiatives. Julie lives in Idaho with her daughter Isabelle who has Bohring-Opitz Syndrome (ASXL1).

$SLS - SELLAS Life Sciences
🔹Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

👆 19.8% PreM/ $1.45

$SLS
- SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level globenewswire.com/news-release/2…

Promising Preliminary Data Shows SLS009's Potential for Treating r/r AML Patients with ASXL1 Mutation: $SLS SELLAS Life Sciences Group recently unveiled encouraging preliminary results… dlvr.it/T6GhQ1 #ClinicalStudy #SLS #MajorPharmaceuticalPreparations #competitors

$SLS SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

$SLS intends to initiate discussions with the U.S. FDA about the potential for an accelerated approval pathway with SLS009 in the ASXL1 molecularly defined r/r AML population as well as in patients harboring this mutation in other indications.

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
globenewswire.com/news-release/2…

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level $SLS healthstockshub.com/news/nasdaq/sl…

$SLS 08:35 on May. 01 2024

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

$sls no position

SELLAS LIFE SCIENCES GROUP INC: 100% OVERALL RESPONSE RATE IN PATIENTS WITH ASXL1 MUTATION IN SLS009 30MG BIW COHORT TO DATE, ALL PATIENTS ALIVE

Novel mechanisms of differentiation in MPNs In Experimental Hematology ISEH from Stephen Oh. Check it out.
exphem.org/article/S0301-…

$SLS SELLAS reports promising Phase 2 results for SLS009 in r/r AML, showing 100% response in ASXL1 mutation patients at optimal dose level.

More Info: pryzm.ozmosi.com/product/22859 $XBI $IBB $XPH $PPH

“Study enrollment ongoing at 30mg BIW dose of SLS009 with expansion cohort of ASXL1 mutation patients; Updates expected in Q3 2024,” $SLS

#SELLASLifeSciencesGroupInc SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level globenewswire.com/news-release/2…

“ASXL1 mutations are associated with poor prognosis in all myeloid diseases, owing to the reduced response to the current treatment options,” said $SLS

$SLS SELLAS reports encouraging Phase 2 results for SLS009 in r/r AML, showing a 100% response rate in patients with ASXL1 mutation at the optimal dose level.

More Info: pryzm.ozmosi.com/product/22859 $XBI $IBB $XPH $PPH

“5/8 (63%) of r/r AML patients, across all dose levels, with ASXL1 truncating mutations treated with SLS009 achieved an overall response; The ASXL1 mutation is found in both hematological malignancies as well as solid tumors,” $SLS